PRIMARY STUDY
Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial
Key Findings: Resulting data revealed that CBD and PEA reduce permeability in the human colon with potential relevance to patients with colitis.
Type of Study: Double Blind Clinical Trial
Study Result: Positive
Research Location(s): United Kingdom
Year of Pub: 2019
Cannabinoids Studied: Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Receptors Studied: CB1, TRPV1, PPAR - Alpha
Citation: Couch DG, et al. Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019; 25:1006-1018. doi: 10.1093/ibd/izz017
Authors: Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE
